GENMAB AS SP.ADR/1/10DK 1 Cash Flow-to-Debt Ratio
GENMAB AS SP.ADR/1/10DK 1 cash flow-to-debt ratio. GENMAB AS SP.ADR/1/10DK 1 (GE91) has a Cash Flow-to-Debt Ratio of 0.04x as of December 2025, meaning its operating cash flow of €301.00 Million could theoretically repay 0% of its total liabilities (€7.03 Billion) in one year. Check GENMAB AS SP.ADR/1/10DK 1 (GE91) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
Cash flow-to-debt ratio of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. Historical debt coverage capacity for GENMAB AS SP.ADR/1/10DK 1 across 5 annual periods. Check cash flow reinvestment rate of GENMAB AS SP.ADR/1/10DK 1 to assess the company's total reinvestment commitment from operating cash flow.
GENMAB AS SP.ADR/1/10DK 1 Cash Flow-to-Debt Ratio by Year (2021–2025)
GENMAB AS SP.ADR/1/10DK 1 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for GENMAB AS SP.ADR/1/10DK 1. For the full cash flow conversion analysis, see GE91 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | €1.19 Billion | €7.03 Billion | ▼ -80.2% |
| 2024 | 0.85x | €1.08 Billion | €1.27 Billion | ▼ -57.5% |
| 2023 | 2.01x | €1.10 Billion | €546.23 Million | ▲ +45.5% |
| 2022 | 1.38x | €563.05 Million | €408.32 Million | ▲ +50.5% |
| 2021 | 0.92x | €339.18 Million | €370.09 Million | — |